Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 7, No 4 (2022)
Review article
Published online: 2022-12-21
View PDF Download PDF file Supp./Additional Files [1]
Get Citation

Effectiveness of laparoscopic sleeve gastrectomy and one anastomosis gastric bypass on the resolution of metabolic syndrome — a review

Aleksander Łukaszewicz1, Piotr Gołaszewski1, Klaudiusz Nadolny23, Jerzy Łukaszewicz1, Jerzy R. Ładny1, Hady Razak Hady1
DOI: 10.5603/MRJ.a2022.0055
·
Medical Research Journal 2022;7(4):340-345.
Affiliations
  1. 1st Department of General and Endocrine Surgery, Medical University of Bialystok, Poland
  2. Faculty of Medicine, Katowice School of Technology, Katowice, Poland
  3. 3rd Department of Health Sciences, WSB University, Dabrowa Gornicza, Poland

open access

Vol 7, No 4 (2022)
REVIEW ARTICLES
Published online: 2022-12-21

Abstract

The main cause of the development of metabolic syndrome seems to be an imbalance of calorie intake and energy expenditure. However genetic and epigenetic factors, sedentary lifestyle, poor food quality, and disturbances in gut microbiota also play a major role. There is no single effective method of treatment for metabolic syndrome. Dietary therapy and an increase in physical activity along with pharmacological treatment are not fully effective to recommend them as a therapy for metabolic syndrome. Today, modern bariatric-metabolic procedures such as laparoscopic sleeve gastrectomy or single anastomosis gastric bypass give the best chances of successful resolution of metabolic syndrome.

Abstract

The main cause of the development of metabolic syndrome seems to be an imbalance of calorie intake and energy expenditure. However genetic and epigenetic factors, sedentary lifestyle, poor food quality, and disturbances in gut microbiota also play a major role. There is no single effective method of treatment for metabolic syndrome. Dietary therapy and an increase in physical activity along with pharmacological treatment are not fully effective to recommend them as a therapy for metabolic syndrome. Today, modern bariatric-metabolic procedures such as laparoscopic sleeve gastrectomy or single anastomosis gastric bypass give the best chances of successful resolution of metabolic syndrome.

Full Text:

View PDF Download PDF file Supp./Additional Files [1]
Get Citation

Keywords

sleeve gastrectomy; one anastomosis gastric bypass; mini gastric bypass; obesity; metabolic syndrome

Supp./Additional Files (1)
Supplementary Figure 1
View
123KB
About this article
Title

Effectiveness of laparoscopic sleeve gastrectomy and one anastomosis gastric bypass on the resolution of metabolic syndrome — a review

Journal

Medical Research Journal

Issue

Vol 7, No 4 (2022)

Article type

Review article

Pages

340-345

Published online

2022-12-21

Page views

3300

Article views/downloads

277

DOI

10.5603/MRJ.a2022.0055

Bibliographic record

Medical Research Journal 2022;7(4):340-345.

Keywords

sleeve gastrectomy
one anastomosis gastric bypass
mini gastric bypass
obesity
metabolic syndrome

Authors

Aleksander Łukaszewicz
Piotr Gołaszewski
Klaudiusz Nadolny
Jerzy Łukaszewicz
Jerzy R. Ładny
Hady Razak Hady

References (59)
  1. World Health Organization. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (12.04.2022).
  2. Kushner RF. Weight loss strategies for treatment of obesity: lifestyle management and pharmacotherapy. Prog Cardiovasc Dis. 2018; 61(2): 246–252.
    CrossRefPubMed
  3. Hanipah ZN, Schauer PR. Bariatric surgery as a long-term treatment for type 2 diabetes/metabolic syndrome. Annu Rev Med. 2020; 71: 1–15.
    CrossRefPubMed
  4. Wojciak PA, Pawłuszewicz P, Diemieszczyk I, et al. Laparoscopic sleeve gastrectomy: a study of efficiency in treatment of metabolic syndrome components, comorbidities and influence on certain biochemical markers. Wideochir Inne Tech Maloinwazyjne. 2020; 15(1): 136–147.
    CrossRefPubMed
  5. Jung JJ, Park AK, Hutter MM. The united states experience with one anastomosis gastric bypass at mbsaqip-accredited centers. Obes Surg. 2022; 32(10): 3239–3247.
    CrossRefPubMed
  6. Han Y, Jia Y, Wang H, et al. Comparative analysis of weight loss and resolution of comorbidities between laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: A systematic review and meta-analysis based on 18 studies. Int J Surg. 2020; 76: 101–110.
    CrossRefPubMed
  7. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018; 20(2): 12.
    CrossRefPubMed
  8. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.
    CrossRefPubMed
  9. Rodríguez JE, Campbell KM. Racial and ethnic disparities in prevalence and care of patients with type 2 diabetes. Clin Diabetes. 2017; 35(1): 66–70.
    CrossRefPubMed
  10. Stierman B, Afful J, Carroll M, et al. National Health and Nutrition Examination Survey 2017–March 2020 Pre-pandemic Data Files. Natl Health Stat Rep. 2021(158): 1–20.
    CrossRef
  11. Eurostat Data Browser. https://ec.europa.eu/eurostat/databrowser/view/hlth_ehis_bm1e/default/table?lang=en (12.04.2022).
  12. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–1645.
    CrossRefPubMed
  13. Després JP. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J Suppl. 2006; 8(suppl_B): B4–B12.
    CrossRef
  14. Zafar U, Khaliq S, Ahmad HU, et al. Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens). 2018; 17(3): 299–313.
    CrossRefPubMed
  15. Bleker LS, de Rooij SR, Painter RC, et al. Cohort profile: the Dutch famine birth cohort (DFBC)— a prospective birth cohort study in the Netherlands. BMJ Open. 2021; 11: e042078.
    CrossRef
  16. Qian Y, Xu H, Wang Y, et al. Obstructive sleep apnea predicts risk of metabolic syndrome independently of obesity: a meta-analysis. Arch Med Sci. 2016; 12(5): 1077–1087.
    CrossRefPubMed
  17. Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022; 46(1): 15–37.
    CrossRefPubMed
  18. Kwon HJ, Pessin JE. 39 Insulin‐Mediated PI3K and AKT Signaling. In: Arias IME, Alter HJ, Boyer JL, Cohen DE, Shafritz A, Thorgeirsson SS, Wolkoff AW. ed. The Liver: Biology and Pathobiology, 6th Edition. Wiley Blackwell, Hoboken 2020: 485–495.
  19. Zafar U, Khaliq S, Ahmad HU, et al. Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens). 2018; 17(3): 299–313.
    CrossRefPubMed
  20. Głuszyńska P, Lemancewicz D, Dzięcioł JB, et al. Non-alcoholic fatty liver disease (NAFLD) and bariatric/metabolic surgery as its treatment option: a review. J Clin Med. 2021; 10(24): 5721.
    CrossRefPubMed
  21. Wu D, Wang H, Xie L, et al. Cross-talk between gut microbiota and adipose tissues in obesity and related metabolic diseases. Front Endocrinol (Lausanne). 2022; 13: 908868.
    CrossRefPubMed
  22. Paley CA, Johnson MI. Abdominal obesity and metabolic syndrome: exercise as medicine? BMC Sports Sci Med Rehabil. 2018; 10: 7.
    CrossRefPubMed
  23. Izquierdo AG, Crujeiras AB, Casanueva FF, et al. Leptin, obesity, and leptin resistance: where are we 25 years later? Nutrients. 2019; 11(11): 2704.
    CrossRefPubMed
  24. Robert M, Espalieu P, Pelascini E, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. Lancet. 2019; 393(10178): 1299–1309.
    CrossRef
  25. World Health Organization. Physical activity. https://www.who.int/news-room/fact-sheets/detail/physical-activity (12.04.2022).
  26. Paley CA, Johnson MI. Abdominal obesity and metabolic syndrome: exercise as medicine? BMC Sports Sci Med Rehabil. 2018; 10: 7.
    CrossRefPubMed
  27. Lei XG, Ruan JQ, Lai C, et al. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2021; 29(6): 985–994.
    CrossRefPubMed
  28. Montan PD, Sourlas A, Olivero J, et al. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med. 2019; 7(16): 393.
    CrossRefPubMed
  29. Konwar M, Bose D, Jaiswal SK, et al. Efficacy and safety of liraglutide 3.0 mg in patients with overweight and obese with or without diabetes: a systematic review and meta-analysis. Int J Clin Pract. 2022; 2022: 1201977.
    CrossRefPubMed
  30. Diemieszczyk I, Głuszyńska P, Gołaszewski P, et al. The effect of laparoscopic sleeve gastrectomy on body mass index and obesity-related diseases in patients over 50 years old. Medical Research Journal. 2022; 7(1): 61–65.
    CrossRef
  31. Grönroos S, Helmiö M, Juuti A, et al. Effect of laparoscopic sleeve gastrectomy vs roux-en-y gastric bypass on weight loss and quality of life at 7 years in patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2021; 156(2): 137–146.
    CrossRefPubMed
  32. Lee WJ, Chong K, Lin YH, et al. Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect. Obes Surg. 2014; 24(9): 1552–1562.
    CrossRefPubMed
  33. Woźniewska P, Diemieszczyk I, Groth D, et al. The influence of patient's age on metabolic and bariatric results of laparoscopic sleeve gastrectomy in 2-year observation. BMC Surg. 2020; 20(1): 323.
    CrossRefPubMed
  34. Martini F, Iannelli A, Treacy P, et al. Perioperative complications of sleeve gastrectomy: review of the literature. J Minim Access Surg. 2019; 15(1): 1–7.
    CrossRefPubMed
  35. Głuszyńska P, Diemieszczyk I, Szczerbiński Ł, et al. Risk factors for early and late complications after laparoscopic sleeve gastrectomy in one-year observation. J Clin Med. 2022; 11(2): 436.
    CrossRefPubMed
  36. Kheirvari M, Dadkhah Nikroo N, Jaafarinejad H, et al. The advantages and disadvantages of sleeve gastrectomy; clinical laboratory to bedside review. Heliyon. 2020; 6(2): e03496.
    CrossRefPubMed
  37. Musella M, Bruni V, Greco F, et al. Conversion from laparoscopic adjustable gastric banding (LAGB) and laparoscopic sleeve gastrectomy (LSG) to one anastomosis gastric bypass (OAGB): preliminary data from a multicenter retrospective study. Surg Obes Relat Dis. 2019; 15(8): 1332–1339.
    CrossRefPubMed
  38. Hutch CR, Sandoval D. The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology. 2017; 158(12): 4139–4151.
    CrossRefPubMed
  39. Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Metabolic and endocrine consequences of bariatric surgery. Front Endocrinol (Lausanne). 2019; 10: 626.
    CrossRefPubMed
  40. Stoica L, Dobrescu A, Isaic A, et al. Metabolic and hormonal changes after sleeve gastrectomy and mini gastric bypass in a rat model of induced type 2 diabetes mellitus and obesity. Chirurgia (Bucur). 2019; 114(6): 732–738.
    CrossRefPubMed
  41. Browning MG, Pessoa BM, Khoraki J, et al. Changes in bile acid metabolism, transport, and signaling as central drivers for metabolic improvements after bariatric surgery. Curr Obes Rep. 2019; 8(2): 175–184.
    CrossRefPubMed
  42. Dong TS, Gupta A, Jacobs JP, et al. Improvement in uncontrolled eating behavior after laparoscopic sleeve gastrectomy is associated with alterations in the brain-gut-microbiome axis in obese women. Nutrients. 2020; 12(10): 2924.
    CrossRefPubMed
  43. Madadi F, Jawad R, Mousati I, et al. Remission of type 2 diabetes and sleeve gastrectomy in morbid obesity: a comparative systematic review and meta-analysis. Obes Surg. 2019; 29(12): 4066–4076.
    CrossRefPubMed
  44. Wölnerhanssen BK, Peterli R, Hurme S, et al. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials (SLEEVEPASS and SM-BOSS). Br J Surg. 2021; 108(1): 49–57.
    CrossRefPubMed
  45. Diemieszczyk I, Woźniewska P, Gołaszewski P, et al. Does weight loss after laparoscopic sleeve gastrectomy contribute to reduction in blood pressure? Pol Arch Intern Med. 2021; 131(7-8): 693–700.
    CrossRefPubMed
  46. Kaya BC, Elkan H. The impact of weight loss after laparoscopic sleeve gastrectomy on early markers of atherosclerotic vascular disease: a prospective study. Kardiol Pol. 2020; 78(7-8): 674–680.
    CrossRefPubMed
  47. Gomes-Rocha SR, Costa-Pinho AM, Pais-Neto CC, et al. CRI-O Group. Roux-en-Y gastric bypass vs sleeve gastrectomy in super obesity: a systematic review and meta-analysis. Obes Surg. 2022; 32(1): 170–185.
    CrossRefPubMed
  48. Rutledge R, Kular K, Manchanda N. The mini-gastric bypass original technique. Int J Surg. 2019; 61: 38–41.
    CrossRefPubMed
  49. Liagre A, Debs T, Kassir R, et al. One anastomosis gastric bypass with a biliopancreatic limb of 150 cm: weight loss, nutritional outcomes, endoscopic results, and quality of life at 8-year follow-up. Obes Surg. 2020; 30(11): 4206–4217.
    CrossRefPubMed
  50. Scavone G, Caltabiano DC, Gulino F, et al. Laparoscopic mini/one anastomosis gastric bypass: anatomic features, imaging, efficacy and postoperative complications. Updates Surg. 2020; 72(2): 493–502.
    CrossRefPubMed
  51. Deitel M, Rutledge R. Mini-gastric bypass: prevention and management of complications in performance and follow-up. Int J Surg. 2019; 71: 119–123.
    CrossRefPubMed
  52. Zorrilla-Nunez LF, Campbell A, Giambartolomei G, et al. The importance of the biliopancreatic limb length in gastric bypass: a systematic review. Surg Obes Relat Dis. 2019; 15(1): 43–49.
    CrossRefPubMed
  53. Felsenreich DM, Langer FB, Eichelter J, et al. Bariatric surgery-how much malabsorption do we need? -A review of various limb lengths in different gastric bypass procedures. J Clin Med. 2021; 10(4): 674.
    CrossRefPubMed
  54. Al-Garzaie A, Alqarzaie AA, Al-Zahrani HA, et al. Laparoscopic reversion of one-anastomosis gastric bypass to normal anatomy: case series and literature review. Am J Case Rep. 2022; 23: e936776.
    CrossRefPubMed
  55. Deitel M. Essentials of Mini – One Anastomosis Gastric Bypass. Springer, Cham 2018: 32–34.
  56. Kular KS, Manchanda N, Rutledge R. Physiology of the MGB: How It Works for Long-Term Weight Loss. In: Deitel M. ed. Essentials of Mini ‒ One Anastomosis Gastric Bypass. Springer, Cham 2018.
  57. Tourky M, Issa M, Salman MA, et al. Nutritional complications after laparoscopic roux-en-y gastric bypass and one-anastomosis gastric bypass: a comparative systematic review and meta-analysis. Cureus. 2022; 14(1): e21114.
    CrossRefPubMed
  58. Robert M, Espalieu P, Pelascini E, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. Lancet. 2019; 393(10178): 1299–1309.
    CrossRef
  59. Magouliotis DE, Tasiopoulou VS, Tzovaras G. One anastomosis gastric bypass versus roux-en-y gastric bypass for morbid obesity: an updated meta-analysis. Obes Surg. 2019; 29(9): 2721–2730.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl